Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TBPH

TBPH - Theravance Biopharma Inc Stock Price, Fair Value and News

$19.01-0.81 (-4.09%)
Market Closed

29/100

TBPH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

29/100

TBPH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$16.19

Target 3M

$18.22

Target 6M

$17.2

TBPH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TBPH Price Action

Last 7 days

-6.7%

Last 30 days

1.6%

Last 90 days

32.9%

Trailing 12 Months

93.4%

TBPH RSI Chart

TBPH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TBPH Valuation

Market Cap

963.3M

Price/Earnings (Trailing)

32.83

Price/Sales (Trailing)

11.99

EV/EBITDA

16.69

Price/Free Cashflow

3.95

TBPH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$16.19

Target 3M

$18.22

Target 6M

$17.2

TBPH Fundamentals

TBPH Revenue

Revenue (TTM)

80.3M

Rev. Growth (Yr)

18.51%

Rev. Growth (Qtr)

-23.69%

TBPH Earnings

Earnings (TTM)

29.3M

Earnings Growth (Yr)

128.47%

Earnings Growth (Qtr)

-93.41%

TBPH Profitability

EBT Margin

58.81%

Return on Equity

12.61%

Return on Assets

7.06%

Free Cashflow Yield

25.3%

TBPH Investor Care

Shares Dilution (1Y)

3.05%

Diluted EPS (TTM)

0.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202565.3M77.2M80.3M0
202461.5M62.0M63.2M64.4M
202348.6M51.3M54.5M57.4M
202254.3M52.4M51.6M51.3M
202166.3M64.2M59.1M55.3M
202087.9M76.8M82.6M71.9M
201957.4M60.1M59.7M73.4M
201820.6M40.6M49.1M60.4M
201733.3M31.4M16.6M15.4M
201640.1M38.5M46.8M48.6M
201531.1M35.3M39.7M42.1M
20141.1M4.1M10.4M11.7M
2013104.3M78.5M52.7M26.9M
2012000130.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Theravance Biopharma Inc

TBPH
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
 CEO
 WEBSITEtheravance.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES111

Theravance Biopharma Inc Frequently Asked Questions

TBPH is the stock ticker symbol of Theravance Biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Theravance Biopharma Inc is 963.28 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check TBPH's fair value in chart for subscribers.

The fair value guage provides a quick view whether TBPH is over valued or under valued. Whether Theravance Biopharma Inc is cheap or expensive depends on the assumptions which impact Theravance Biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TBPH.

As of Wed Jan 28 2026, TBPH's PE ratio (Price to Earnings) is 32.83 and Price to Sales (PS) ratio is 11.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TBPH PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Theravance Biopharma Inc has provided 0.015 (multiply by 100 for percentage) rate of return.